High-dose metoclopramide has been proposed as an effective antiemetic agent in patients treated with cisplatin. Its optimal dosage schedule, however, has not yet been completely defined. We report the results of a multicenter, double-blind, randomized clinical trial where the efficacy and safety of two fixed high-dose regimens of metoclopramide (60 and 120 mg, respectively) have been tested in 112 patients receiving cisplatin treatment. No statistically significant difference has been found between the two groups. In patients treated with cisplatin at doses greater than 100 mg/m2, the higher dose regimen seems more efficacious, but this result should be confirmed in a larger group of patients. Treatment was generally well-tolerated. However, a consistent percentage of patients (about 60%) still present with vomiting, and this makes further investigation necessary.

Roila, F., Tonato, M., Basurto, C., Canaletti, R., Morsia, D., Passalacqua, R., et al. (1985). Antiemetic activity of two different high doses of metoclopramide in cisplatin-treated cancer patients: A randomized double-blind trial of the Italian Oncology Group for Clinical Research. CANCER TREATMENT REPORTS, 69(12), 1353-1357.

Antiemetic activity of two different high doses of metoclopramide in cisplatin-treated cancer patients: A randomized double-blind trial of the Italian Oncology Group for Clinical Research

COLOMBO, NICOLETTA;
1985

Abstract

High-dose metoclopramide has been proposed as an effective antiemetic agent in patients treated with cisplatin. Its optimal dosage schedule, however, has not yet been completely defined. We report the results of a multicenter, double-blind, randomized clinical trial where the efficacy and safety of two fixed high-dose regimens of metoclopramide (60 and 120 mg, respectively) have been tested in 112 patients receiving cisplatin treatment. No statistically significant difference has been found between the two groups. In patients treated with cisplatin at doses greater than 100 mg/m2, the higher dose regimen seems more efficacious, but this result should be confirmed in a larger group of patients. Treatment was generally well-tolerated. However, a consistent percentage of patients (about 60%) still present with vomiting, and this makes further investigation necessary.
Articolo in rivista - Articolo scientifico
Male; Metoclopramide; Random Allocation; Middle Aged; Female; Italy; Neoplasms; Double-Blind Method; Humans; Age Factors; Sex Factors; Clinical Trials as Topic; Aged; Adult; Vomiting; Cisplatin
English
1985
69
12
1353
1357
none
Roila, F., Tonato, M., Basurto, C., Canaletti, R., Morsia, D., Passalacqua, R., et al. (1985). Antiemetic activity of two different high doses of metoclopramide in cisplatin-treated cancer patients: A randomized double-blind trial of the Italian Oncology Group for Clinical Research. CANCER TREATMENT REPORTS, 69(12), 1353-1357.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/27517
Citazioni
  • Scopus 31
  • ???jsp.display-item.citation.isi??? 31
Social impact